atopic eczema: A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
405 |
4. Check minimum number of eventsNone |
405 |
5. Include endpointsNone |
405 |
6. Filter based on genotype QC (FinnGen only) |
399 |
Control definitions (FinnGen only)
- Control exclude
- L12_DERMATITISECZEMA
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L20-L30
- Name in latin
- Erythrodermia universalis NAS
Similar endpoints
↥List of similar endpoints to
Exfoliative dermatitis
based on the number of shared cases.
Similar with more cases:
- Dermatitis and eczema
- Diseases of the skin and subcutaneous tissue
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 3058 | 1077 | 1960 |
| Only index persons | 2575 | 944 | 1631 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.05 | 0.03 | 0.05 |
| Only index persons | 0.05 | 0.03 | 0.06 |
| Median age at first event (years) | |||
| Whole population | 61.96 | 61.58 | 62.08 |
| Only index persons | 60.41 | 60.15 | 60.56 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 399 | 118 | 281 |
| Unadjusted period prevalence (%) | 0.10 | 0.04 | 0.13 |
| Median age at first event (years) | 61.87 | 56.30 | 64.20 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 405
- Matched controls
- 4050
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D07AB08
ATC
desonide; topical
38.7
317.6
250
162
L26
ICD-10 Finland
Exfoliative dermatitis
+∞
307.7
353
*
E000001, ,
ATC
24.4
247.1
278
333
E000003, ,
ATC
48.2
220.5
136
42
TQW80
NOMESCO Finland
Local dermatologic skincare
82.0
192.6
104
17
D07AA02
ATC
hydrocortisone; topical
17.1
186.7
211
242
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
18.3
171.7
168
151
L30.9
ICD-10 Finland
Dermatitis, unspecified
15.6
169.7
196
229
D07AC01
ATC
betamethasone; topical
19.4
169.1
334
789
L20.0
ICD-10 Finland
Besnier prurigo
+∞
165.2
147
*
D05BB02
ATC
acitretin; oral
48.2
164.1
99
27
E0000UV, ,
ATC
20.7
162.3
345
880
E000002, ,
ATC
16.1
154.7
162
161
134
Kela drug reimbursment
General erythroderma
362.7
149.2
142
6
D02AE01
ATC
carbamide; topical
20.1
145.7
126
89
D07AB02
ATC
hydrocortisone butyrate; topical
12.4
145.0
279
613
D07XC01
ATC
betamethasone; topical
11.9
129.7
174
242
L30.3
ICD-10 Finland
Infective dermatitis
56.4
128.6
74
16
D07AC13
ATC
mometasone; topical
10.3
126.3
257
584
D02AX
ATC
Other emollients and protectives
35.9
124.6
81
28
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
11.9
122.1
156
202
E000006, ,
ATC
16.4
118.1
112
92
L40.0
ICD-10 Finland
Psoriasis vulgaris
21.6
117.1
94
56
L04AD01
ATC
ciclosporin; systemic
45.2
112.4
68
18
D07BA04
ATC
hydrocortisone and antiseptics; topical
12.5
110.1
128
144
XQ802
NOMESCO Finland
Epicutan test
47.2
95.6
57
14
317
Kela drug reimbursment
Topical pimecrolimus and tacrolimus
+∞
94.6
87
*
L04AX03
ATC
methotrexate; systemic
10.2
94.4
129
178
D07AD01
ATC
clobetasol; topical
8.4
89.4
153
274
H02AB06
ATC
prednisolone; systemic
8.4
79.9
324
1302
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
12.3
79.3
87
88
E000007, ,
ATC
15.4
76.2
71
55
D11AH01
ATC
tacrolimus; topical
404.4
68.8
67
*
N05BB01
ATC
hydroxyzine; systemic
11.2
68.0
79
86
D05AX52
ATC
calcipotriol, combinations; topical
11.6
64.4
72
74
WXQ27
NOMESCO Finland
UVB narrow spectrum light therapy
154.3
62.9
65
5
L20.9
ICD-10 Finland
Atopic dermatitis, unspecified
+∞
57.7
54
*
R06AE07
ATC
cetirizine; oral
4.9
55.9
243
945
D05AX02
ATC
calcipotriol; topical
13.1
52.6
53
46
R06AE09
ATC
levocetirizine; oral
5.8
47.5
105
231
XQ800
NOMESCO Finland
Prick test
9.8
45.5
56
65
D09AB01
ATC
zinc bandage without supplements; topical
64.6
44.6
51
9
D11AX14
ATC
[U] tacrolimus
+∞
42.4
40
*
D07BC01
ATC
betamethasone and antiseptics; topical
5.7
42.4
93
202
L04AA01
ATC
[U] ciclosporin
54.6
37.5
44
9
R06AX27
ATC
desloratadine; oral
4.0
37.3
149
515
L20
ICD-10 Finland
Atopic dermatitis
+∞
36.0
34
*
D11AH02
ATC
pimecrolimus; topical
+∞
36.0
34
*
L30.0
ICD-10 Finland
Nummular dermatitis
10.4
33.8
39
41
C84.0
ICD-10 Finland
Mycosis fungoides
111.6
29.1
31
*
D07CC01
ATC
betamethasone and antibiotics; topical
4.2
27.2
84
237
395
Kela drug reimbursment
Dupilumab
+∞
26.3
25
*
D11AH05
ATC
dupilumab; topical
+∞
25.3
24
*
D07AC14
ATC
methylprednisolone aceponate; topical
6.5
24.9
43
73
L40.8
ICD-10 Finland
Other psoriasis
40.3
24.3
30
8
319
Kela drug reimbursment
Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis)
40.3
24.3
30
8
XQ848
NOMESCO Finland
Dermatological photography
9.4
23.6
29
33
L40.9
ICD-10 Finland
Psoriasis, unspecified
26.6
23.4
32
13
A46
ICD-10 Finland
Erysipelas
3.5
23.4
99
344
69100
ICD-8 Finland
Infantile eczema and related conditions, Eczema atopicum. Prurigo Besnier. Eczema pruriginosum allergicum
+∞
23.1
22
*
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
3.1
22.6
124
504
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
46.1
21.7
26
6
L04AX01
ATC
azathioprine; systemic
6.5
21.6
37
62
E000004, ,
ATC
19.2
21.2
32
18
H02AB07
ATC
prednisone; oral
3.5
20.6
85
289
L27.0
ICD-10 Finland
Generalized skin eruption due to drugs and medicaments
58.0
19.1
22
*
L01BA01
ATC
methotrexate; systemic
6.3
19.0
33
56
J30.10
ICD-10 Finland
Allergic rhinitis due to pollen
6.2
18.2
32
55
L30.8
ICD-10 Finland
Other specified dermatitis
17.6
18.1
28
17
L23.0
ICD-10 Finland
Allergic contact dermatitis due to metals
+∞
17.8
17
*
D05AX03
ATC
calcitriol; topical
16.6
17.8
28
18
R06AX22
ATC
ebastine; oral
3.2
17.6
82
299
EBA15
NOMESCO Finland
Extraction of multiple teeth
5.7
17.1
33
62
D11AX15
ATC
[U] pimecrolimus
+∞
16.8
16
*
6918B
ICD-9 Finland
Atopic dermatitis and related conditions, Other atopic dermatitis and related conditions[ECZEMA ATOPICUM]
+∞
16.8
16
*
RS340, ,
NOMESCO Finland
177.0
16.6
17
*
Z2446
NOMESCO Finland
Social worker
4.2
16.5
47
123
J45.0
ICD-10 Finland
Predominantly allergic asthma
4.0
16.4
50
138
J01DB01
ATC
cefalexin; oral
3.2
16.2
347
2634
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.0
15.9
81
310
L44.0
ICD-10 Finland
Pityriasis rubra pilaris
+∞
15.7
15
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.3
15.4
221
1381
H02AB04
ATC
methylprednisolone; systemic
3.0
15.2
80
311
S01GX01
ATC
cromoglicic acid; ophthalmic
2.9
15.1
80
313
L23.3
ICD-10 Finland
Allergic contact dermatitis due to drugs in contact with skin
155.4
14.6
15
*
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
3.4
14.3
57
188
S87
ICPC
Dermatitis/atopic eczema
12.0
14.0
25
22
L40
ICD-10 Finland
Psoriasis
11.5
13.7
25
23
A41.0
ICD-10 Finland
Sepsis due to Staphylococcus aureus
6.2
13.7
24
41
L28.1
ICD-10 Finland
Prurigo nodularis
+∞
13.6
13
*
L20.8
ICD-10 Finland
Other atopic dermatitis
+∞
13.6
13
*
WXQ12
NOMESCO Finland
Psoralen - Ultraviolet A therapy with local sensitivisation
+∞
13.6
13
*
WXQ10
NOMESCO Finland
Psoralen - Ultraviolet A therapy with systemic sensitivisation
+∞
13.6
13
*
H02AB09
ATC
hydrocortisone; systemic
10.2
12.9
25
26
L50.0
ICD-10 Finland
Allergic urticaria
11.5
12.7
23
21
C01CA24
ATC
epinephrine; parenteral
4.1
12.5
36
95
J01FF01
ATC
clindamycin; systemic
2.3
12.1
127
681
F10.1
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Harmful use
3.3
12.0
47
153
ZXD31
NOMESCO Finland
Major difficulties in performing procedure
5.5
11.7
23
44
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
2.4
11.6
98
479
L23.2
ICD-10 Finland
Allergic contact dermatitis due to cosmetics
+∞
11.5
11
*
9700/3-C44.9
ICD-O-3
Mycosis fungoides of skin, NOS
+∞
11.5
11
*
C84.1
ICD-10 Finland
Sézary disease
+∞
11.5
11
*
L40.5
ICD-10 Finland
Arthropathic psoriasis
12.3
11.5
20
17
RS221, ,
NOMESCO Finland
12.3
11.5
20
17
RJ411, ,
NOMESCO Finland
36.1
11.3
14
*
ZX112
NOMESCO Finland
Subcutaneous
5.8
11.3
21
38
R06AX13
ATC
loratadine; oral
2.7
11.2
65
265
L53.9
ICD-10 Finland
Erythematous condition, unspecified
12.4
10.9
19
16
D06AX01
ATC
fusidic acid; topical
2.9
10.5
53
200
L27.2
ICD-10 Finland
Dermatitis due to ingested food
+∞
10.5
10
*
J45.9
ICD-10 Finland
Asthma, unspecified
2.4
10.4
81
380
6961A
ICD-9 Finland
Psoriasis and similar disorders, Other psoriasis[PSORIASIS VULGARIS]
33.5
10.4
13
*
L23.9
ICD-10 Finland
Allergic contact dermatitis, unspecified cause
33.5
10.4
13
*
RS121, ,
NOMESCO Finland
19.4
10.3
15
8
L50.9
ICD-10 Finland
Urticaria, unspecified
4.8
10.1
23
50
L29.9
ICD-10 Finland
Pruritus, unspecified
10.4
10.1
19
19
S91
ICPC
Psoriasis
17.2
9.9
15
9
RJ420, ,
NOMESCO Finland
26.8
9.9
13
5
L28.0
ICD-10 Finland
Lichen simplex chronicus
56.4
9.7
11
*
J01DA09
ATC
[U] cefadroxil
2.1
9.7
113
626
SPAT1148
SPAT
Treatment of chronic ulcer or burn
2.5
9.7
68
304
L23.8
ICD-10 Finland
Allergic contact dermatitis due to other agents
+∞
9.4
9
*
D11AH04
ATC
alitretinoin; oral
+∞
9.4
9
*
S21
ICPC
Skin texture symptom/complaint
2.6
9.2
60
258
JN4BD
NOMESCO Finland
Extensive body CT
2.5
9.0
59
254
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.0
8.8
132
798
L08.0
ICD-10 Finland
Pyoderma
20.5
8.5
12
6
M07.3*L40.5
ICD-10 Finland
Other psoriatic arthropathies
8.1
8.5
18
23
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.6
8.4
50
206
S01GX02
ATC
levocabastine; ophthalmic
4.0
8.4
24
63
6929X
ICD-9 Finland
Contact dermatitis and other eczema, Unspecified cause[DERMATITITIS ARTEFACTA NUD]
+∞
8.4
8
*
J44.8
ICD-10 Finland
Other specified chronic obstructive pulmonary disease
2.3
8.3
68
324
R21
ICD-10 Finland
Rash and other nonspecific skin eruption
4.1
8.3
23
59
D64.9
ICD-10 Finland
Anaemia, unspecified
2.4
8.2
58
259
WW200
NOMESCO Finland
Immunization
4.9
8.2
18
38
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
22.5
8.1
11
5
S02
ICPC
Pruritus
4.6
8.0
19
43
SPAT1254
SPAT
Administration of medicine
2.2
7.7
71
355
P15
ICPC
Chronic alcohol abuse
4.1
7.7
21
53
J01DA01
ATC
[U] cefalexin
1.8
7.7
244
1843
C10AB05
ATC
fenofibrate; oral
6.4
7.6
19
31
JN4AD
NOMESCO Finland
Body CT examination
2.5
7.5
48
204
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
2.3
7.4
57
264
WQ021, ,
NOMESCO Finland
+∞
7.3
7
*
L40.1
ICD-10 Finland
Generalized pustular psoriasis
+∞
7.3
7
*
L23.5
ICD-10 Finland
Allergic contact dermatitis due to other chemical products
+∞
7.3
7
*
R03AK06
ATC
salmeterol and fluticasone; inhalant
2.2
7.0
66
333
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
3.7
7.0
22
62
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.8
6.9
151
1016
D07XB05
ATC
dexamethasone; topical
5.8
6.8
18
32
C03CA01
ATC
furosemide; systemic
1.8
6.8
148
992
RJ421, ,
NOMESCO Finland
40.8
6.8
8
*
RS311, ,
NOMESCO Finland
23.0
6.7
9
*
RS224, ,
NOMESCO Finland
23.0
6.7
9
*
X59
ICD-10 Finland
Exposure to unspecified factor
2.0
6.7
78
427
H10
ICD-10 Finland
Conjunctivitis
3.1
6.7
28
95
J18.9
ICD-10 Finland
Pneumonia, unspecified
1.8
6.7
124
792
L04AB04
ATC
adalimumab; parenteral
8.9
6.6
13
15
J45
ICD-10 Finland
Asthma
2.6
6.5
38
155
L04AC16
ATC
guselkumab; systemic
70.9
6.4
7
*
M10.9
ICD-10 Finland
Gout, unspecified
2.6
6.4
38
156
D07AC03
ATC
desoximetasone; topical
6.7
6.4
15
23
S01AD03
ATC
aciclovir; ophthalmic
3.8
6.3
19
52
69282
ICD-8 Finland
Other eczema and dermatitis, E microbis
+∞
6.3
6
*
1XX25, ,
NOMESCO Finland
+∞
6.3
6
*
6929B
ICD-9 Finland
Contact dermatitis and other eczema, Unspecified cause[ECZEMA INFECTIOSUM]
+∞
6.3
6
*
ZX196, ,
NOMESCO Finland
+∞
6.3
6
*
L04AC05
ATC
ustekinumab; parenteral
27.1
6.2
8
*
RS211, ,
NOMESCO Finland
27.1
6.2
8
*
D07XA01
ATC
hydrocortisone; topical
27.1
6.2
8
*
L01AA02
ATC
chlorambucil; oral
27.1
6.2
8
*
M10.0
ICD-10 Finland
Idiopathic gout
3.5
6.2
21
62
ZY010
NOMESCO Finland
Hospital outpatient
3.1
6.2
25
83
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
104
133
10.18
80.03
2.0
1.2
3585.76
221.61
u/ml
5.51
99
117
110
365
3.76
28.38
5.5
4.4
258.58
245.43
u/l
0.40
105
345
250
1410
3.02
25.65
13.8
5.8
4.27
2.89
%
7.25
245
1317
285
1746
3.13
24.83
17.7
9.0
4.46
4.22
e9/l
1.23
267
1520
249
1450
2.86
23.22
14.2
6.0
24.03
26.67
%
3.49
244
1361
33
16
22.34
22.96
2.2
1.9
—
—
—
0
0
93
325
3.42
21.69
5.6
3.5
—
—
—
0
0
76
252
3.48
19.11
1.8
3.1
67.07
65.84
g/l
0.80
68
224
27
19
15.13
16.56
3.0
2.1
414.29
331.85
e6/l
0.39
17
13
24
35
7.23
15.87
1.1
1.1
9.19
1.87
u/ml
0.98
17
20
29
60
5.13
13.53
4.0
3.3
62.41
57.32
%
1.09
29
60
28
57
5.20
13.30
3.9
3.0
4.82
4.34
e9/l
0.47
28
57
18
9
20.85
12.56
1.8
1.0
11.24
7.71
ug/l
—
18
9
38
112
3.64
11.27
1.5
2.5
3.88
3.62
g/l
0.89
32
97
38
112
3.64
11.27
1.5
2.5
7.40
7.32
g/l
0.10
32
97
38
112
3.64
11.27
1.5
2.5
—
—
—
0
0
34
93
3.90
11.21
1.6
2.9
0.70
0.95
g/l
0.12
27
79
88
418
2.41
11.03
8.9
6.3
1.07
1.04
mmol/l
0.66
82
385
101
513
2.29
10.85
4.5
3.9
0.78
0.82
mmol/l
3.05
92
485
35
102
3.66
10.55
1.5
2.6
3.13
3.10
g/l
0.05
29
87
131
768
2.04
9.62
2.6
2.0
2.87
3.18
mg/l
0.79
112
658
287
2202
2.04
9.59
5.7
3.9
15.18
12.35
mm/h
1.91
280
2007
33
102
3.43
9.11
1.5
2.5
10.31
10.56
g/l
0.16
27
87
14
10
14.45
8.75
1.2
1.5
11.46
19.01
umol/l
—
14
10
299
2364
2.01
8.69
11.7
7.9
84.32
78.85
u/l
1.04
289
2207
190
1308
1.85
8.39
6.8
5.1
34.32
35.21
g/l
1.23
176
1229
12
7
17.62
8.12
2.3
1.6
—
—
—
0
0
29
90
3.39
7.96
1.6
2.6
37.11
37.50
g/l
0.12
23
75
81
435
2.08
7.35
3.1
2.6
25.29
22.82
%
0.64
76
382
101
590
1.95
7.24
1.4
1.2
4.64
1.24
u/ml
0.85
30
160
174
1210
1.77
7.10
3.4
2.7
203.83
169.60
ug/l
0.61
161
1103
113
690
1.88
7.07
2.9
2.7
4.43
3.86
e6/l
0.35
103
618
170
1184
1.75
6.84
4.0
3.3
—
—
—
0
0
24
74
3.38
6.66
1.2
1.7
—
—
—
0
0
175
1241
1.72
6.52
2.3
1.9
87.24
94.66
pmol/l
1.78
126
655
21
62
3.52
6.23
1.4
1.8
—
—
—
0
0
24
79
3.17
6.02
2.6
1.8
—
—
—
0
0
214
1628
1.67
5.96
8.4
6.9
10.34
12.07
umol/l
2.85
206
1543
19
55
3.58
5.80
1.0
1.3
—
—
—
0
0
35
146
2.53
5.72
1.6
2.3
1.60
1.46
g/l
0.35
28
129
112
727
1.75
5.58
1.9
1.5
19.98
19.90
nmol/l
0.01
100
614
119
789
1.72
5.48
3.6
2.9
382.46
9490.32
umol/l
4.11
104
686
96
599
1.79
5.46
1.9
1.7
1177.33
1210.30
nmol/l
0.13
75
461
157
1123
1.65
5.42
2.7
2.3
72.25
76.78
nmol/l
1.29
147
988
24
85
2.94
5.34
1.2
1.3
—
—
—
0
0
45
218
2.20
5.28
2.2
1.7
—
—
—
0
0
143
1006
1.65
5.23
3.7
3.4
48.27
137.71
e6/l
0.73
119
783
135
937
1.66
5.20
2.2
2.1
326.02
277.83
u/l
0.14
129
882
15
40
3.86
5.13
1.2
1.2
—
—
—
0
0
15
32
4.83
5.04
1.2
1.3
—
—
—
0
0
200
1539
1.59
5.01
16.7
15.6
1.23
1.29
inr
0.57
63
446
141
1003
1.62
4.87
4.2
3.5
2.34
2.34
mmol/l
0.20
120
878
19
62
3.17
4.85
2.2
2.5
16.54
15.99
%
—
10
34
26
102
2.66
4.82
2.8
4.5
70.12
134.44
mg/l
0.45
18
80
26
102
2.66
4.82
2.8
4.5
34.02
34.46
mg/l
0.03
18
81
196
1514
1.57
4.75
9.5
7.1
1.20
1.21
mmol/l
0.17
155
1273
7
5
14.21
4.59
1.0
1.0
—
—
—
0
0
22
86
2.65
4.12
2.2
1.4
—
—
—
0
0
252
2102
1.53
4.04
5.4
3.5
14.71
14.90
pmol/l
0.56
234
1861
229
1876
1.51
3.98
6.1
4.9
6.99
6.79
mmol/l
0.49
220
1760
12
27
4.55
3.96
1.2
1.1
—
—
—
0
0
177
1382
1.50
3.84
8.6
6.3
1.20
1.21
mmol/l
0.19
166
1240
126
920
1.54
3.73
3.7
3.3
0.30
0.54
e6/l
1.08
107
700
11
25
4.49
3.65
1.3
1.2
—
—
—
0
0
60
366
1.75
3.63
2.3
1.8
2.10
1.57
%
3.27
55
320
15
51
3.02
3.61
1.9
1.7
—
—
—
0
0
13
36
3.70
3.52
3.8
2.5
—
—
—
0
0
13
40
3.32
3.17
2.1
2.9
34.62
33.38
pg
0.68
13
40
6
8
7.59
3.06
1.2
1.0
1823.00
1182.50
miu/ml
—
6
8
10
26
3.92
3.00
1.6
3.3
—
—
—
0
0
20
88
2.34
2.98
1.4
1.4
—
—
—
0
0
38
215
1.85
2.96
4.8
3.8
1.21
1.71
mmol/l
0.30
32
157
50
308
1.71
2.94
5.4
4.5
1.73
1.77
mmol/l
0.02
40
245
64
422
1.61
2.91
1.4
1.5
—
—
—
0
0
128
981
1.45
2.89
3.7
3.9
5.89
9.90
mg/mmol
1.18
87
660
14
53
2.70
2.82
1.4
1.1
—
—
—
0
0
14
53
2.70
2.82
1.4
1.1
—
—
—
0
0
76
527
1.54
2.79
2.4
1.9
—
—
—
0
0
129
997
1.43
2.76
2.5
2.5
49.37
55.66
u/l
2.07
121
927
7
14
5.07
2.74
9.9
9.9
765.71
918.57
nmol/l
—
7
14
7
14
5.07
2.74
13.0
11.8
1094.00
1617.57
nmol/l
—
7
14
15
60
2.56
2.73
3.3
2.0
—
—
—
0
0
10
29
3.51
2.71
1.7
1.8
—
—
—
0
0
179
1472
1.39
2.66
5.9
4.9
0.00
0.00
estimate
-0.00
54
292
10
30
3.39
2.62
1.2
1.2
—
68.00
—
0
5
181
1495
1.38
2.61
4.4
3.6
0.00
0.00
estimate
-0.00
51
278
109
832
1.42
2.47
4.3
3.7
0.00
0.01
estimate
0.50
49
283
89
655
1.46
2.45
1.9
1.8
390.03
429.99
pmol/l
0.59
77
548
10
32
3.18
2.45
1.1
1.1
—
—
—
0
0
125
979
1.40
2.45
3.1
3.2
7.62
8.17
mmol/l
0.62
106
822
179
1488
1.36
2.43
4.4
3.6
0.00
0.00
estimate
0.50
53
314
6
12
5.06
2.41
6.0
2.9
101.17
95.08
%
—
6
12
5
8
6.31
2.38
1.2
1.0
—
—
—
0
0
56
377
1.56
2.34
3.0
3.3
5.04
9.82
umol/l
3.96
51
340
18
85
2.17
2.32
3.3
1.8
—
—
—
0
0
18
85
2.17
2.32
3.6
1.8
—
—
—
0
0
230
1998
1.35
2.30
4.4
3.2
74.29
52.49
u/l
1.38
222
1860
11
40
2.80
2.29
1.7
1.8
—
—
—
0
0
7
18
3.94
2.26
1.3
1.1
—
—
—
0
0
7
18
3.94
2.26
1.7
1.9
—
—
—
0
0
7
18
3.94
2.26
1.7
1.9
—
—
—
0
0
16
73
2.24
2.24
2.3
2.1
137.00
131.55
g/l
0.40
11
51
44
283
1.62
2.23
2.4
2.2
53.89
204.46
u/l
0.42
36
239
5
9
5.61
2.22
6.8
2.2
—
—
—
0
0
77
565
1.45
2.15
4.5
3.2
2.45
2.44
mmol/l
0.20
64
496
8
25
3.24
2.10
1.8
1.7
—
—
—
0
0
14
62
2.30
2.10
1.2
1.3
—
—
—
0
0
6
15
4.04
2.04
1.3
1.3
—
—
—
0
0
8
26
3.12
2.02
1.0
1.2
—
—
—
0
0
143
1175
1.34
2.02
4.5
3.7
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
21
112
1.92
2.00
3.8
2.7
0.39
0.31
u/ml
0.37
13
65
125
1010
1.34
1.97
3.3
3.3
3023.22
1625.34
ng/l
0.58
116
872
5
11
4.59
1.94
4.8
2.2
76440.00
39900.45
ug/l
—
5
11
12
52
2.35
1.89
1.6
1.7
—
—
—
0
0
87
669
1.38
1.87
2.2
1.7
1.93
1.46
mg/l
0.56
65
524
6
17
3.57
1.84
1.0
1.2
—
—
—
0
0
60
433
1.45
1.83
1.4
1.3
4.58
14.29
u/ml
1.65
23
177
12
53
2.30
1.82
1.3
1.2
—
—
—
0
0
17
88
1.97
1.77
1.1
1.2
—
—
—
0
0
17
88
1.97
1.77
1.1
1.2
—
—
—
0
0
13
61
2.17
1.73
1.8
1.7
—
—
—
0
0
5
13
3.88
1.72
2.4
1.0
—
—
—
0
0
17
90
1.93
1.67
1.2
1.3
—
—
—
0
0
21
120
1.79
1.65
1.9
1.7
—
—
—
0
0
22
128
1.76
1.64
3.3
1.9
—
—
—
0
0
12
56
2.18
1.62
1.9
1.8
—
—
—
0
0
12
56
2.18
1.62
1.4
1.2
—
—
—
0
0
5
14
3.60
1.62
1.0
1.4
—
—
—
0
0
5
14
3.60
1.62
1.0
1.4
—
—
—
0
0
24
144
1.71
1.61
6.5
4.4
24.94
24.89
mmol/l
0.02
24
134
51
367
1.45
1.59
2.0
1.9
—
—
—
0
0
13
245
0.52
1.58
1.8
1.7
—
—
—
0
0
13
64
2.07
1.56
1.3
1.5
—
—
—
0
0
5
15
3.36
1.53
1.0
1.5
—
—
—
0
0
5
15
3.36
1.53
1.0
1.5
—
—
—
0
0
7
27
2.62
1.52
1.1
1.0
—
—
—
0
0
325
3053
1.33
1.47
26.6
15.2
24.33
26.07
mg/l
0.47
296
2427
5
16
3.15
1.44
1.0
1.4
—
—
—
0
0
5
16
3.15
1.44
1.0
1.4
—
—
—
0
0
6
23
2.63
1.37
1.0
1.2
—
—
—
0
0
93
757
1.30
1.36
4.2
2.5
—
—
—
0
0
0
37
0.00
1.35
0.0
1.2
—
7.74
—
0
30
30
201
1.53
1.34
1.5
1.6
—
—
—
0
0
59
452
1.36
1.31
1.4
1.3
24.82
37.97
iu/ml
0.61
23
145
5
18
2.80
1.29
2.4
4.1
—
—
—
0
0
70
554
1.32
1.26
3.1
3.0
0.79
0.91
e6/l
0.18
44
325
287
2676
1.25
1.23
5.8
4.2
1.86
2.41
mu/l
0.62
269
2396
8
37
2.19
1.22
1.0
1.7
—
—
—
0
0
49
370
1.37
1.20
1.9
1.8
—
—
—
0
0
75
604
1.30
1.19
3.3
3.8
887.84
463.81
ng/l
0.47
63
496
76
928
0.78
1.18
2.9
3.1
0.52
0.80
ug/l
6.32
57
606
10
50
2.03
1.17
2.1
1.8
—
—
—
0
0
13
72
1.83
1.16
1.5
1.5
28254.67
12660.95
e6/l
—
6
55
8
39
2.07
1.16
1.6
1.6
—
—
—
0
0
25
167
1.53
1.15
3.7
3.6
23.85
24.85
mmol/l
0.62
25
161
8
40
2.02
1.12
1.6
1.6
—
—
—
0
0
8
40
2.02
1.12
1.6
1.6
—
—
—
0
0
8
40
2.02
1.12
1.6
1.5
—
—
—
0
0
8
41
1.97
1.09
4.6
2.0
—
—
—
0
0
8
41
1.97
1.09
2.0
1.7
—
—
—
0
0
8
41
1.97
1.09
1.6
1.5
—
—
—
0
0
8
41
1.97
1.09
1.6
1.5
—
—
—
0
0
8
41
1.97
1.09
2.0
1.7
—
—
—
0
0
12
67
1.82
1.05
1.8
1.5
230.80
247.22
miu/ml
—
5
33
146
1289
1.21
1.03
4.5
3.8
46.74
42.17
ng/l
0.10
108
958
9
47
1.94
1.02
1.6
1.2
—
56.50
—
0
5
18
116
1.58
0.98
2.7
3.3
—
—
—
0
0
21
144
1.48
0.89
1.3
1.3
—
—
—
0
0
159
1433
1.18
0.87
4.1
2.7
—
—
—
0
0
29
215
1.38
0.83
1.9
1.5
—
—
—
0
0
65
540
1.24
0.83
3.5
3.2
1.68
1.52
e6/l
0.12
38
315
6
33
1.83
0.79
1.0
1.1
—
—
—
0
0
7
121
0.57
0.79
3.0
1.6
—
—
—
0
0
8
48
1.68
0.79
1.8
1.7
—
—
—
0
0
13
82
1.60
0.79
1.5
1.3
—
—
—
0
0
0
26
0.00
0.78
0.0
1.2
—
—
—
0
0
5
99
0.50
0.78
1.0
1.6
—
—
—
0
0
37
289
1.31
0.77
2.2
2.7
9.18
8.21
ug/l
0.12
32
263
12
75
1.62
0.75
1.5
1.5
—
—
—
0
0
7
40
1.76
0.71
4.7
4.3
363.71
326.01
umol/l
—
7
34
9
57
1.59
0.71
4.7
1.9
—
—
—
0
0
9
57
1.59
0.71
4.7
1.9
—
—
—
0
0
301
2885
1.17
0.68
25.0
14.1
79.89
79.02
ml/min/173m2
0.25
272
2405
18
248
0.71
0.67
1.9
1.4
—
—
—
0
0
28
216
1.32
0.65
3.4
3.4
129.79
129.20
g/l
0.04
28
211
114
1264
0.86
0.65
3.6
4.3
16.49
21.53
%
2.91
52
618
5
30
1.67
0.61
1.8
2.2
—
—
—
0
0
292
3032
0.87
0.61
5.9
4.9
2.58
2.68
mmol/l
1.03
271
2771
22
286
0.76
0.59
2.6
1.9
—
—
—
0
0
6
35
1.72
0.58
2.3
4.0
—
—
—
0
0
6
38
1.59
0.54
5.7
2.1
—
—
—
0
0
148
1592
0.89
0.52
4.4
5.0
3.79
2.87
ug/l
0.26
128
1407
20
252
0.78
0.45
2.8
1.8
—
—
—
0
0
47
408
1.17
0.42
8.9
7.1
1.38
1.14
mmol/l
0.12
35
317
5
33
1.52
0.41
1.4
1.2
—
—
—
0
0
5
34
1.48
0.40
1.2
1.1
—
—
—
0
0
5
34
1.48
0.40
1.0
1.2
258.00
188.67
pmol/l
—
5
34
168
1773
0.91
0.39
3.0
2.9
—
—
—
0
0
38
328
1.17
0.37
2.1
2.0
13.83
13.68
nmol/l
0.03
38
288
6
47
1.28
0.32
1.2
1.1
—
—
—
0
0
7
53
1.33
0.31
1.7
1.4
—
—
—
0
0
288
2944
0.92
0.27
5.5
4.4
1.35
1.39
mmol/l
1.27
267
2692
27
235
1.16
0.26
4.3
3.4
59.55
65.45
ml/min/173m2
0.47
11
96
36
400
0.89
0.23
3.9
4.7
29.15
31.30
%
0.43
26
273
334
3388
0.92
0.23
42.1
21.9
39.83
40.31
%
0.78
318
3177
7
93
0.75
0.22
2.7
1.5
—
—
—
0
0
7
93
0.75
0.22
1.3
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.6
—
—
—
0
0
6
48
1.25
0.20
1.5
1.3
91.00
14.74
e6/l
—
6
42
6
48
1.25
0.20
1.5
1.3
10.00
174.17
e6/l
—
6
42
38
346
1.11
0.20
2.5
4.9
4.80
49.69
ug/l
1.20
31
292
0
14
0.00
0.20
0.0
2.7
—
—
—
0
0
321
3166
1.07
0.18
28.0
17.8
3.98
4.00
mmol/l
0.84
315
3082
7
63
1.11
0.17
2.1
1.1
36.74
52.59
u/l
—
7
52
71
674
1.06
0.16
4.7
3.6
1.02
1.02
kg/l
0.28
11
97
81
773
1.06
0.15
2.0
1.6
1.44
1.38
mmol/l
0.27
68
632
292
2959
0.95
0.14
6.5
4.5
4.42
4.51
mmol/l
0.89
273
2722
319
3158
1.05
0.12
27.9
17.6
139.03
139.71
mmol/l
4.66
314
3077
16
143
1.12
0.11
1.0
1.0
—
—
—
0
0
276
2792
0.96
0.10
6.4
6.0
39.91
40.72
mmol/mol
0.67
257
2573
289
2862
1.03
0.09
6.2
4.0
1.42
1.30
mmol/l
1.90
269
2602
5
62
0.80
0.08
1.2
1.3
—
—
—
0
0
7
65
1.08
0.08
1.1
1.2
—
—
—
0
0
295
2933
1.02
0.04
5.2
4.6
6.07
6.06
mmol/l
0.04
277
2654
16
153
1.05
0.01
1.4
1.3
—
37.66
—
0
13
37
371
1.00
0.00
12.7
7.0
—
—
—
0
0
0
5
0.00
0.00
0.0
3.4
—
—
—
0
0
6
65
0.92
0.00
1.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
4.40
—
0
5
0
7
0.00
0.00
0.0
1.0
—
21.91
—
0
7
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
69.40
—
0
5
0
5
0.00
0.00
0.0
3.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.8
—
13.26
—
0
8
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_EXFOLIATIVE and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_EXFOLIATIVE | 2.068 [1.66, 2.57] | < 0.001 |
| Birth year | 0.991 [0.98, 1.0] | 0.049 |
During the follow-up period (1.1.1998 — 31.12.2019), 324 out of 966 females with L12_EXFOLIATIVE died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_EXFOLIATIVE | 2.357 [1.97, 2.82] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.004 |
During the follow-up period (1.1.1998 — 31.12.2019), 723 out of 1728 males with L12_EXFOLIATIVE died.
Mortality risk
Mortality risk for people of age
years, who have L12_EXFOLIATIVE.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.14% | 0.419% |
| 5 | 1.185% | 2.546% |
| 10 | 2.717% | 6.481% |
| 15 | 5.238% | 11.839% |
| 20 | 9.028% | 19.972% |
Relationships between endpoints
↥Index endpoint: L12_EXFOLIATIVE – Exfoliative dermatitis
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data